Author information
- 1Division of Digestive and Liver Diseases Comprehensive Transplant Center Cedars Sinai Medical Center Los Angeles California.
- 2Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore.
- 3Division of Gastroenterology and Hepatology National University Hospital National University Health System Singapore.
- 4Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University School of Medicine Richmond Virginia.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western populations, and is closely associated with features of the metabolic syndrome. The burden of disease is set to rise exponentially, and this is further compounded by the lack of good medications. In addition, these patients tend to have multiple comorbidities that may not be adequately managed. In this article, we review the biological basis of potential therapies in nonalcoholic steatohepatitis (NASH), the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic.
